NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718
Human autologous T lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:autologous anti-MAGE-A3/A6 TCR-transduced T cells KITE-718
MAGE-A3/A6 T cell receptor engineered T cells
MAGE-A3/A6 T cell receptor engineered T cells KITE-718
MAGE-A3/A6 TCR engineered T lymphocytes
MAGEA3/A6-targeted TCR-transduced T cells KITE-718
TCR-transduced autologous T cells KITE-718
Code name:KITE 718